We are pleased to announce we have submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new treatment in frontline myelofibrosis. The submission is based on the results of the Phase 3 SENTRY trial that were recently presented at ASCO, EHA and published in a peer-reviewed journal. Patients living with myelofibrosis continue to face significant unmet need, and our team is committed to advancing potential treatment options. To learn more click here: bit.ly/4qVBjWz

Today we released our Q2 financial results and highlighted near term milestones in our myelofibrosis program that have the potential to transform the future of Karyohparm for all our stakeholders. To read our latest developments click here: bit.ly/3TWMBxp

Karyopharm to Report Second Quarter 2026 Financial Results and Share Upcoming Milestones on Thursday, August 13, 2026 at 8:00 AM Eastern. Learn more here: bit.ly/4x0ZAg7

This Uterine Cancer Awareness Month, Karyopharm is joining the @IGCSociety to help improve awareness and understanding of this disease. Recognizing symptoms and seeking care early can play an important role in improving outcomes. We are advocating for education, awareness, and conversations that can help drive earlier detection for women facing uterine cancer. #UterineCancerAwarenessMonth #EndometrialCancer #EarlyDetection #IGCS #Oncology #CancerAwareness

Our CEO, Richard Paulson, recently appeared on #BioTech TV where he discussed our research into the maintenance of response in endometrial cancer that is TP53 Wild-Type. In the interview Richard explains our research and upcoming Phase 3 data readout for XPORT-EC-042. To view the full interview click here lnkd.in/eeJ2-wfM

New data from our Phase 3 SENTRY trial in myelofibrosis were featured in a late-breaking oral presentation at #EHA2026. Our CEO, Richard Paulson, spoke with #BiotechTV at EHA about the impact of myelofibrosis on patients and why new treatments are needed. To view the full interview, click here bit.ly/49YTkfy

New Phase 3 data from our SENTRY trial in myelofibrosis were featured in a late-breaking oral presentation at the @EHA_Hematology (EHA) Annual Congress on June 14. The EHA Scientific Program Committee highlighted these findings as one of the top presentations at the meeting. To view the presentation slides, click here: bit.ly/3Q1PSdn #EHA

June is Uterine Cancer Awareness Month. At Karyopharm, we are proud to stand with the @IGCSociety to raise awareness of endometrial cancer and support patients, caregivers, and advocates around the world. Too many women are unaware of the subtle signs and symptoms of uterine cancer—contributing to delays in diagnosis and care. Together, we aim to amplify awareness, increase education and advance conversations around uterine cancer. #UCAM #EndometrialCancer #IGCS #Jump4June #Oncology

We are pleased to announce new data from our Phase 3 SENTRY trial in myelofibrosis has been selected as one of the top presentations at the European Hematology Association (EHA)'s annual congress by the Scientific Program Committee. The late-breaking oral presentation will be delivered on June 14th. To learn more please click here: bit.ly/43Olh5X #EHA2026

Today we're excited to present new data from our Phase 3 SENTRY trial in myelofibrosis in a late-breaking oral presentation at #ASCO26. To learn more click here: bit.ly/4e3aFVN Results to be published simultaneously in the @JCO_ASCO . To view the manuscript, click here: bit.ly/3RIPmkT #JCO

Just a few days until #ASCO26. We’re looking forward to sharing new data from our Phase 3 SENTRY trial in #myelofibrosis in a late-breaking oral presentation. If you’re going to Chicago, stop by Booth #33155 to meet our passionate team and learn about our unique science. Check out the details of our oral presentation #ASCO2026: bit.ly/4fbiWcm See you soon.

Today we released our Q1 financial results and highlighted near term milestones in our endometrial cancer and myelofibrosis programs that have the potential to transform the future of Karyopharm for all our stakeholders. To read our latest developments: bit.ly/4nva2bO

Karyopharm to participate at two upcoming investor conferences on May 19th. Click here to read the press release: bit.ly/3R1JDWZ

Karyopharm to Report First Quarter 2026 Financial Results and Share Upcoming Milestones on May 14, 2026. Learn more here: bit.ly/4tlv4Lq

Just wrapped an exciting weekend at the @SOncology70650 Annual Meeting on Women's Cancer sharing news and learnings with our peers. The dedication and commitment of our peers around the world is inspiring and empowering as we at Karyopharm work towards making a difference for women with endometrial cancer.

Today we announced the topline results from our Phase 3 SENTRY trial in frontline #myelofibrosis. We would like to thank the patients, families, caregivers, investigators and clinical trial teams that participated in this trial. We will be hosting a conference call at 8:00am ET to discuss the results. Read the press release here: bit.ly/4rUqxia

February 28 is rare disease day which recognizes the more than 300 million people living with a rare disease. Karyopharm stands in solidarity with the rare disease community and is committed to improving the lives of patients suffering from rare diseases. Our work is fueled by the belief in the extraordinary strength and courage of patients. #BelieversinPatients #LightUpForRare #RareDiseaseDay #SupportAndSolidarity